NRX Pharmaceuticals enters $2M at-the-market equity offering with H.C. Wainwright

NRX Pharmaceuticals, Inc.

At-the-market offering of up to $2,000,000 of common stock; sales at market prices via Nasdaq.
H.C. Wainwright will receive 3.0% commission on gross proceeds plus expense reimbursement.
Sales are made under an effective shelf registration statement (S-3) filed June 2022.
Company is not obligated to sell any shares; agreement terminates upon full sale or earlier termination.
Customary reps, warranties, indemnification, and conditions apply to the agreement.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

NRX Pharmaceuticals, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at up to $2,000,000 (effective 2023-08-14).

Action: entry
Agreement: atm program
Counterparty: H.C. Wainwright & Co., LLC
Value: up to $2,000,000
Effective: 2023-08-14

Exact text from the filing

On August 14, 2023, NRX Pharmaceuticals, Inc. (the “Company”), entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), as sales agent, pursuant to which the Company may offer and sell, from time to time through Wainwright, shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $2,000,000 (the “Shares”).

View on SEC.gov

Browse all material agreements →

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-091494

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.